Your Health, We Care
Balversa has been approved in the United States and multiple other countries for the treatment of eligible patients with urothelial carcinoma. As the first FDA approved oral FGFR inhibitor, edatinib holds significant importance in the field of cancer treatment.
Balversais an oral anticancer drug targeting FGFR mutations for the treatment of···【more】
Release date：2024-08-26Recommended：234
Balversais a new oral anti-cancer drug targeting FGFR, which is specially design···【more】
Release date：2024-08-26Recommended：214
Balversais an oral tyrosine kinase inhibitor for the treatment of non-small cell···【more】
Release date：2024-08-26Recommended：184
